"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
-
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. MMWR Morb Mortal Wkly Rep. 2025 Aug 28; 74(32):508-514.
-
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLoS One. 2025; 20(6):e0325561.
-
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J Hematol Oncol. 2024 08 14; 17(1):67.
-
89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors. Mol Cancer Ther. 2024 Jun 04; 23(6):890-903.
-
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. J Infect Dis. 2024 03 14; 229(3):671-679.
-
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med. 2023 05; 12(10):11248-11253.
-
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells. Mol Cancer Ther. 2020 08; 19(8):1682-1695.
-
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
-
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.